Is bladder biopsy necessary at three or six months post BCG therapy?

Area of Science:

• Urology
• Oncology
• Medical Diagnostics

Background:

• The standard follow-up for superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG) involves cystoscopy and bladder biopsy at 3 months.
• This protocol aims to assess treatment efficacy and detect recurrence promptly.

Purpose of the Study:

• To determine if routine bladder biopsies are necessary at 3 or 6 months post-BCG therapy for superficial bladder cancer.
• To evaluate the diagnostic accuracy of cystoscopy alone in assessing treatment response.

Main Methods:

• Retrospective chart review of 43 patients treated with a 6-weekly course of BCG (Connaught strain) for high-grade or recurrent Ta, T1, or Tis bladder cancer.
• Patients received maintenance therapy based on disease stage and were followed for 6 months, with cystoscopies and biopsies performed as clinically indicated.

Main Results:

• At 3 months, 32/43 patients had negative cystoscopies with corresponding negative biopsies.
• Eight patients showed visible papillary tumors, and three had biopsy-negative erythematous lesions.
• At 6 months, eight different patients were diagnosed with superficial bladder cancer via biopsy after visible lesions on cystoscopy.
• The positive predictive value of cystoscopy was 72.6% at 3 months and 100% at 6 months, with a 7% false positive rate at 3 months.

Conclusions:

• Bladder biopsy is not essential at the 3 or 6-month follow-up points after BCG therapy if cystoscopic findings are negative.
• Negative cystoscopy in the context of BCG therapy for superficial bladder cancer appears to reliably rule out residual or recurrent disease.